Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 3 for:    CV8102
Previous Study | Return to List | Next Study

Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03291002
Recruitment Status : Recruiting
First Posted : September 25, 2017
Last Update Posted : January 22, 2021
Sponsor:
Collaborator:
Syneos Health
Information provided by (Responsible Party):
CureVac AG

Brief Summary:

This study evaluates intratumoral administration of CV8102 in patients with advanced melanoma, squamous cell carcinoma of the skin, squamous cell carcinoma of the head and neck, or adenoid cystic carcinoma.

Patients will receive CV8102 as single agent or in combination with SoC anti-PD-1 therapy.


Condition or disease Intervention/treatment Phase
Melanoma (Skin) Squamous Cell Carcinoma of the Skin Carcinoma, Squamous Cell of Head and Neck Carcinoma, Adenoid Cystic Biological: CV8102 Biological: CV8102 + anti-PD-1 therapy Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 98 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Intervention Model Description: Open-label, cohort-based, dose escalation and expansion study
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I Study of Intratumoral CV8102 in Patients With Advanced Melanoma, Squamous Cell Carcinoma of the Skin, Squamous Cell Carcinoma of the Head and Neck, or Adenoid Cystic Carcinoma
Actual Study Start Date : September 25, 2017
Estimated Primary Completion Date : October 2022
Estimated Study Completion Date : February 2023


Arm Intervention/treatment
Experimental: Cohort A
Dose escalation of CV8102
Biological: CV8102
CV8102 alone

Experimental: Cohort B
Optional expansion cohorts of CV8102
Biological: CV8102
CV8102 alone

Experimental: Cohort C
Dose escalation of CV8102 + anti-PD-1 therapy
Biological: CV8102 + anti-PD-1 therapy
CV8102 in combination with standard of care anti-PD-1 therapy

Experimental: Cohort D
Optional expansion of CV8102 + anti-PD-1 therapy
Biological: CV8102 + anti-PD-1 therapy
CV8102 in combination with standard of care anti-PD-1 therapy




Primary Outcome Measures :
  1. Dose determination for dose escalation cohorts [ Time Frame: 2 weeks ]
    • Maximum tolerated dose (MTD) and recommended dose (RD), respectively, for CV8102 alone
    • MTD and recommended combination dose (RCD) for CV8102 in combination with the standard dose of an anti-PD-1 antagonist

  2. Incidence of treatment related (Serious) Adverse Events (Tolerability and Safety profile) [ Time Frame: up to 12 months (end of study) ]
    • Tolerability and safety profile of CV8102 alone and in combination with anti-PD-1 antagonists


Secondary Outcome Measures :
  1. Tumor response [ Time Frame: up to 12 months (end of study) ]
    • Anti-tumor activity of CV8102 per irRECIST and RECIST 1.1

  2. Disease status [ Time Frame: 6 months ]
    • Tumor Assessment

  3. Tumor response [ Time Frame: up to 12 months (end of study) ]
    • Extent of tumor response at injected and non-injected lesions, if applicable

  4. Survival [ Time Frame: up to 12 months (end of study) ]
    • Survival time



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria:

  1. Patients enrolled into Cohorts A and B (single agent CV8102) must have:

    • histologically confirmed advanced cutaneous melanoma, cutaneous squamous cell carcinoma, head and neck squamous cell carcinoma, or adenoid cystic carcinoma with documented disease progression
    • not amenable to surgical resection or locoregional radiation therapy with curative intent
    • at least 1 line of anti-cancer therapy for advanced disease (except adenoid cystic carcinoma) and documented Progression
    • cutaneous melanoma Cohort B3: Willing to undergo baseline and post-baseline biopsy of the lesion which is to be injected
  2. Patients enrolled into Cohort C (CV8102 in combination with anti-PD-1 therapy) must have

    • histologically confirmed advanced cMEL or hnSCC
    • indication for anti-PD-1 therapy or currently receiving anti-PD-1 therapy with stable of slowly progressing disease after at last 8 weeks (hnSCC) or 12 weeks (cMEL) of anti-PD-1 therapy prior to Day 1
  3. Patients enrolled into Cohort D1 (CV8102 in combination with anti-PD-1 therapy) must have

    • histologically confirmed advanced cMEL
    • either anti-PD-1 naive patients with indication for anti-PD-1 therapy (Cohort D1a) or patients refractory to anti-PD-1 therapy (Cohort D1b)
    • Presence of measurable lesion(s) according to RECIST 1.1, not intended for injection
    • Willing to undergo tumor biopsies at specific timepoints (Cohort D1a: baseline; Cohort D1b baseline and post-baseline biopsy of the injected lesion - only for selected sites)
  4. Patients enrolled into Cohort D2 (CV8102 in combination with anti-PD-1 therapy) must have

    • histologically confirmed advanced hnSCC
    • indication for treatment with first-line pembrolizumab (patients naive to anti-PD-1/anti-PD-L1)
    • PD-L1 combined positive score ≥ 1% according to local practice
  5. Presence of at least one injectable tumor lesion that is measurable according to RECIST 1.1
  6. Recovered from prior toxicities to CTCAE grade ≤ 1 or grade ≤ 2
  7. Resolution of CPI-related adverse effects, if applicable (including irAEs) back to CTCAE grade 0/1
  8. ECOG PS 0 or 1
  9. 18 years of age or older
  10. Adequate hematologic, renal, hepatic and coagulation function
  11. Use of effective contraception

Key Exclusion Criteria:

  1. Rapidly progressing multi-focal metastatic or acutely life threatening disease
  2. Prior use of topical/localTLR-7/8 agonists within the past 6 months
  3. Clinically active central nervous system metastases and/or carcinomatous meningitis (patients with stable brain metastases are eligible)
  4. Ocular and mucosal melanoma
  5. Prior anti-cancer therapy within specified time-periods depending on the indication
  6. Tumor lesions that are to be injected close to major blood vessels or nerves, or whose injection could potentially result in clinical adverse effects if post-treatment tumor swelling or inflammation were to occur
  7. Lesions that are to be injected in previously irradiated areas unless progressive tumor growth has been demonstrated (no prior irradiation of injected lesions on patients with melanoma)
  8. History of active coagulation or bleeding disorder or need for ongoing therapeutic anticoagulation that cannot be safely interrupted at th etime of IT injection or biopsy du eto Underlying medical conditions; patients with melanoma and cutaneous squamous cell carcinoma with controlled oral anticoagulation are eligible
  9. Treatment with any investigational anticancer agent within 30 days or 5 half-lives (whichever is longer) prior to the first dose of study drug or planned during the study
  10. Acute hypophysitis or endocrinopathies that are not adequately controlled by hormonal replacement therapy or thyreostatic treatment
  11. Use of immune modulating drugs or immunologically active topical therapies within 28 days of administration of the first dose of study drug
  12. Chronic systemic immunosuppressive therapy including chronic corticosteroids within 28 days of the first dose of study drug (except physiological maintenance/replacement steroid doses, topical steroids outside the injected lesion or inhaled steroids); patients are eligible if steroid requirement is < 10 mg/day of prednisone (or equivalent) for at least 2 weeks
  13. History of active autoimmune disease requiring immunosuppressive medication (except Vitiligo and except CPI-mediated irAEs)
  14. Known hematologic malignancy or malignant primary solid tumor that have occured or reoccurred within the previous 5 years
  15. Recent thromboembolic complications, or clinically significant cardiovascular disease, or any other uncontrolled illness that would pose a risk to patient safety
  16. Severe infection or acute inflammatory state
  17. Seropositivity for human immunodeficiency virus (HIV), hepatitis B virus (HBV) surface antigen (except in previously vaccinated patients) or hepatitis C virus (HCV)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03291002


Contacts
Layout table for location contacts
Contact: Thomas Eigentler, Prof. Dr. +49 7071 298 4553 thomas.eigentler@med.uni-tuebingen.de

Locations
Show Show 23 study locations
Sponsors and Collaborators
CureVac AG
Syneos Health
Investigators
Layout table for investigator information
Principal Investigator: Thomas Eigentler, Prof. Dr. thomas.eigentler@med.uni-tuebingen.de
Layout table for additonal information
Responsible Party: CureVac AG
ClinicalTrials.gov Identifier: NCT03291002    
Other Study ID Numbers: CV-8102-008
First Posted: September 25, 2017    Key Record Dates
Last Update Posted: January 22, 2021
Last Verified: January 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma
Melanoma
Carcinoma, Squamous Cell
Skin Neoplasms
Squamous Cell Carcinoma of Head and Neck
Carcinoma, Adenoid Cystic
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms, Nerve Tissue
Nevi and Melanomas
Neoplasms, Squamous Cell
Neoplasms by Site
Skin Diseases
Head and Neck Neoplasms
Adenocarcinoma